VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been formally appointed as a director. This appointment is made pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The board's decision to make these changes is intended to ensure that it continues to meet Helix's evolving governance and capital markets requirements. The new composition is designed to provide the experience and expertise needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
These board changes come at a critical time for Helix as it advances its clinical programs and seeks to position itself in the competitive oncology landscape. The appointment of Dr. Mehrling, who has been leading the company's strategic direction, signals a strong alignment between management and the board. This move may enhance decision-making efficiency and reinforce confidence among investors and partners.
The resignation of Mr. Grabski and the appointment of Dr. Mehrling reflect a broader trend in biotech governance where companies realign board composition to better match their strategic phases. As Helix progresses its pipeline candidates, having a CEO on the board could facilitate more direct oversight and quicker pivots in strategy.
Helix's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). The company continues to focus on addressing unmet medical needs in oncology through innovative therapies.
For more information about Helix BioPharma and its pipeline, visit the company's website at https://www.helixbiopharma.com/. Details about the acquisition from Laevoroc Group can be found at this link.
